16 September 2026 editorial review · Item
Ixekizumab (I-DIT / IL-17A blockade): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: new record; substantive review 16 September 2026.
- Scope and findings: Added I-DIT entry. Checked current registry, planned rather than actual sample, eligibility and lack of posted outcomes; January 2026 US Taltz label checked for indications and material warnings.
- Primary sources checked: NCT04589325 — study record (registry); Taltz (ixekizumab) US prescribing information, revised January 2026 (regulatory).
- Limits: No demonstrated T1D effect or specific T1D harms rates. Other-country labels and stock were not surveyed.